SUPPLEMENTARY NOTES

Elucidating the clinical and molecular spectrum of *SMARCC2*-associated NDD in a cohort of 65 affected individuals

SUPPLEMENTARY METHODS

Cohort

Two out of 41 novel individuals were included in previous publications with either incomplete clinical or molecular findings. More specifically, the Ind-18 variant (c.172C>T p.(Gln58*)) had previously been described in a publication, but the clinical description was missing. ¹ Ind-25, with the variant c.1094_1097del p.(Lys365Thrfs*12), was also reported in a recent case report and was included in the current cohort due to the description of significant additional clinical and molecular findings. ² The novel individuals were recruited either via an international collaborative network of research and diagnostic sequencing centers or by employing the webbased matching platform GeneMatcher ³ and posting a call for a collaborative project in ERN-ITHACA (European Network of Rare Malformation Syndromes).

Genetic analysis

Two of the five affected individuals in Fam-18 (Ind-22 and Ind-23) and Ind-42 were identified by Sanger sequencing as having the familial *SMARCC2* variant. Targeted Sanger sequencing utilizing standard methods was also performed, either for confirmation of identified variants or segregation analysis in the absence of trio exome data.

The previously published *SMARCC2* variants of 17 clinically characterized individuals ^{2,4,5}, five cases with DD/ID or autism spectrum disorder (ASD) without further clinical description, a fetus with cardiac defects and a newborn with a diaphragmatic hernia who died in the perinatal period ^{1,6–8} were reviewed and included in File S2 sheets "clinical_table" and protein linear model.

Clinical Information

Using a standardized questionnaire, clinical, phenotypic, and neuroimaging data were collected from the referring physicians. For the extraction of clinical information on previously reported individuals, the same questionnaire was used. Facial features were determined independently by two clinical geneticists, either from the respective clinical report or from analysis of the published pictures. Brain MRI data were reviewed by an experienced pediatric neuroradiologist. For the cases without available MRI images neuroimaging data were obtained from the reports. Face2Gene research application was applied to a single 2D frontal facial photograph of a total of 23 novel and previously published individuals (10 with missense/in-frame and 13 with LGD variants). Individuals wearing glasses in the available photos or carrying a second pathogenic/likely pathogenic variant in another gene were excluded.

RNA isolation, RT-PCR and qRT-PCR

Total RNA was extracted from untransformed blood lymphocytes of Ind-19 and his unaffected brother, Ind-29 and one control individual with the PAXgene Blood System (Becton Dickinson). cDNA was prepared with a Superscript II Reverse Transcriptase Kit (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's instructions. RT-PCR for In-29 was performed with the Platinum PCR SuperMix High Fidelity kit (Invitrogen), using primers encompassing exons 18-20 of SMARCC2 gene (NM 003075.5) (18F: 5'- CAGACCTCTGCTTCCCAAC-3' and 20R: 5'-CAGCAGCAGAGGCGACTC-3'). PCR products were purified using the GenUP Exo SAP kit (BiotechRabbit, Berlin, Germany) and sequenced by the Big Dye Terminator Cycle Sequencing kit (Applied Biosystems, Foster City, CA, USA). SMARCC2 expression levels of Ind-19 were analyzed by qRT-PCR with predesigned Taqman gene-expression assay (SMARCC2: Hs00161961 m1) on an ABI 7900HT instrument (ThermoFisher Scientific). For normalization of results to the mean, the following endogenous controls were used: b-actin (huACTB), b-2 microglobulin (huB2M), acidic ribosomal protein (huPO), and phosphoglycerate kinase 1 (huPGK1) (all Thermo Fisher Scientific). Reactions were performed in four replicates. mRNA levels were calculated with the DDCt method.

Cell Culture

HEK293T cells were grown in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal calf serum (FCS) and 1% penicillin/streptomycin at 37°C in 5% CO2. Plasmids were transfected with JetPrime® (Polyplus Life Science) according to manufacturer's instructions.

Plasmids and Mutagenesis

Flag-tagged SMARCC2 was obtained from addgene (plasmid #19142) and has previously been described ⁹. Mutagenesis was carried out using the In-Fusion HD Cloning kit (Clontech). Oligonucleotide sequences are provided in Table S4.

Immunofluorescence, PLA and Microscopy

Cells were grown on coverslips. 24 h after transfection, they were fixed in 3.7 % formaldehyde for 10 min at room temperature, permeabilized for 10 min in 0.5 % Triton-X-100 and washed in PBS. Antibodies were diluted in PBS containing 5 % normal goat serum. Cells were incubated with the primary antibody (mouse monoclonal FLAG, Sigma F1804) for 1 h at 37 °C and washed in PBS containing 0.1 % Tween20, followed by incubation with the Cy3-conjugated secondary antibody (dianova 115-165-146) for 1 h at 37 °C and another wash. Coverslips were mounted using ProLong[™] Antifade mountant (Thermo Fisher Scientific).

For PLA, cells were seeded onto coverslips 17 h post transfection and fixed and permeabilized as described above 30 h post transfection. PLA was performed using Duolink In Situ reagents (Sigma) according to the manufacturer's instructions. All slides were imaged on a Zeiss AxioImager Z2 with Apotome using the AxioVision software and processed using AxioVision and ImageJ.

Immunoprecipitation and Western Blotting

Whole cell lysate was generated as previously described. ¹⁰ Briefly, cells were washed in PBS and rotated in buffer A (10 mM HEPES, pH 7.9; 10 mM KCl; 0.1 mM EDTA, pH 8.0; 0.1 mM EGTA, pH 8.0; 2 mM DTT; 10 µg/ml Aprotinin; 10 µg/ml Leupeptin; 1 % NP-40; 300 mM NaCl) for 15 min at 4 °C. Following centrifugation at 16000 x g for 5 min, protein concentration was determined using the Qubit[™] Protein Assay-kit (Thermo Fisher Scientific).

For Co-immunoprecipitation of FLAG-tagged SMARCC2, 2 mg whole cell lysate of transfected or untransfected cells (to control for nonspecific antibody binding) was incubated in CoIPbuffer (10 mM HEPES, pH 7.9; 0.1 mM EDTA, 0.1 mM EGTA, 120 mM NaCl, 10 % glycerol) at 4 °C overnight with 4 µg of mouse monoclonal FLAG (Sigma F1804), 8 µg of rabbit polyclonal FLAG (Sigma F7425) or no antibody (to control for nonspecific binding to beads) and pulled down by incubation for 3 h at 4 °C with magnetic SureBeads[™] (BioRad). Following 3 washes in CoIP-buffer, proteins were eluted twice in 50 µl 2x Lämmli-buffer at 90 °C for 5 minutes each.

15 μl of the IP fraction were run on 4-15 % gradient polyacrylamide gels and transferred onto nitrocellulose membranes using semi-dry blotting. Membranes were blocked in 5 % non-fat dry milk in TBS and incubated with antibodies in 3 % non-fat dry milk in TBS-T. Incubation with primary antibodies occurred overnight at 4 °C. Following three washes in TBS-T, secondary antibodies were incubated for 1 h at room temperature. Membranes were developed with SuperSignal[™] West Femto Maximum Sensitivity Substrate (Thermo Scientific) and imaged on a ChemiDoc Imaging System (BioRad). Protein bands were quantified by densitometry using the software ImageLab (BioRad).

Antibodies

All antibodies used in this work are listed in Table S5.

SUPPLEMENTARY RESULTS

Additional variants in SMARCC2 individuals

Along with the *SMARCC2* frameshift variant, Ind-25 and Ind-33 carried a likely pathogenic splice variant in the *TANC2* gene (MIM 615047), which is linked to an NDD with autistic features and language delay (MIM 618906) and a pathogenic 1p36 microdeletion, respectively. In addition to the *de novo* in-frame *SMARCC2* variant, Ind-34 had a *de novo* likely pathogenic missense substitution in the *ACSL4* gene, which was linked to the NDD X-linked 63 entity (MIM 300387). Of note, Ind-42 additionally carried a maternally inherited pathogenic *RAF1* (MIM 164760) variant linked to dilated cardiomyopathy (MIM 615916); this was not detected in the affected older sister (Ind-35).

Prevalence of clinical manifestations in literature vs novel SMARCC2 cases

The majority of the clinical manifestations and dysmorphic facial features were found to have similar frequencies between the previously published *SMARCC2* subjects and the novel cohort (Table 1 and 2 and Table S1). Moderate/severe global DD/ID and muscular hypotonia seemed to be more common in the literature, while mild developmental impairment and autistic behavior described more often in this cohort. The novel cohort had a lower prevalence for both congenital anomalies of the genitourinary system and gastrointestinal tract as well as for the facial feature broad philtrum. However, after correction for multiple testing, p-values for all aforementioned traits remained not significant. The only clinical features which remained significantly lower in novel subjects after correction were the eye structural abnormalities and outer ear anomalies (FDR corrected p-value: 0.029 and 0.034, respectively) (Table 2).

Clinical reports

Ind-01 case report

Removed to comply with medRxiv policy.

Ind-02 case report

Removed to comply with medRxiv policy.

Ind-03 case report

Removed to comply with medRxiv policy.

Ind-04 case report

Ind-05 case report

Removed to comply with medRxiv policy.

Ind-06 case report

Removed to comply with medRxiv policy.

Ind-07 case report

Removed to comply with medRxiv policy.

Ind-08 case report

Removed to comply with medRxiv policy.

Ind-09 case report

Removed to comply with medRxiv policy.

Ind-10 case report

Removed to comply with medRxiv policy.

Ind-11 case report

Removed to comply with medRxiv policy.

Ind-12 case report

Removed to comply with medRxiv policy.

Ind-13 case report

Removed to comply with medRxiv policy.

Ind-14 case report

Removed to comply with medRxiv policy.

Ind-15 case report

Removed to comply with medRxiv policy.

Ind-16 (Family-16) case report

Removed to comply with medRxiv policy.

Ind-17 (Family-16) case report

Ind-18 case report

Removed to comply with medRxiv policy.

Family 18 (Ind-19, Ind-20, Ind-21, Ind-22, Ind-23)

Removed to comply with medRxiv policy.

Ind-19 case report

Removed to comply with medRxiv policy.

Ind-20 case report

Removed to comply with medRxiv policy.

Ind-21 case report

Removed to comply with medRxiv policy.

Ind-22 case report

Removed to comply with medRxiv policy.

Ind-23 case report

Removed to comply with medRxiv policy.

Ind-25 case report

Removed to comply with medRxiv policy.

Ind-26 case report

Removed to comply with medRxiv policy.

Ind-29 case report

Removed to comply with medRxiv policy.

Ind-31 case report

Removed to comply with medRxiv policy.

Ind-32 case report

Removed to comply with medRxiv policy.

Ind-33 case report

Ind-34 case report

Removed to comply with medRxiv policy.

Ind-35 (Family-26) case report

Removed to comply with medRxiv policy.

Ind-36 case report

Removed to comply with medRxiv policy.

Ind-37 case report

Removed to comply with medRxiv policy.

Ind-38 case report

Removed to comply with medRxiv policy.

Ind-39 case report

Removed to comply with medRxiv policy.

Ind-40 case report

Removed to comply with medRxiv policy.

Ind-41 case report

Removed to comply with medRxiv policy.

Ind-42 (Family-26) case report

Removed to comply with medRxiv policy.

Ind-43 case report

Removed to comply with medRxiv policy.

Ind-45 case report

SUPPLEMENTARY FIGURES



Figure S1 | SMARCC2 domain structure with variant distribution, sequence conservation and clustering regions

(A) Linear model of SMARCC2 (see main Figure 1A for variant descriptions). (B) Density plot depicting distribution of missense and truncating variants over the protein length. Missense variants are found mainly in the central region of the protein, occurring in the SANT, DR and CAR domains, but a cluster is also present in the N-terminal module. Truncating variants instead are found throughout the protein. (C) Generalized linear model of CADD PHRED scores for all possible missense variants of *SMARCC2*. The blue line shows smoothed CADD values, while the red horizontal line shows the recommended score cutoff (20). Shaded areas indicate protein domains. SMARCC2 and its functional domains are highly conserved.



Figure S2 | Non-truncating variants in SMARCC2 in the BAF 3D-model by He et al.

(A) Cartoon model of the BAF complex (based on PDB structure 6LTH ¹¹). For experimental reasons, this model was built on a BAF complex containing not a SMARCC1/SMARCC2 heterodimer, but a SMARCC2/SMARCC2 homodimer. The two chains are named SMARCC2 (a) and SMARCC2 (b) respectively. Because the SMARCC1/C2 BAF complex generated an almost identical cryo-EM map and both SMARCC proteins contain the same highly conserved domains and bind other BAF subunits in a similar manner¹¹, the assumptions made on the CC2/CC2 model are transferable to the CC1/CC2 model. The subunits contained in this model are indicated. The herein described novel variants are depicted in red, previously published variants in magenta. (B) and (C) Zoom of the SANT domains of the respective SMARCC2 (a) and (b) proteins. The non-truncating variants affecting amino acid positions Arg599, Leu609, Leu610, Leu613, Cys635, and Leu640 are depicted as red spheres. Note the close proximity of two of the only three described SMARCD1 missense variants ¹² indicated in magenta: c.1483T>C p.(Phe495Leu) in (B) and c.1336A>G p.(Arg446Gly) in (C), respectively. The regions affected by these variants form the palm and thumb of the base module scaffold as defined by He and colleagues ¹¹. The close proximity of missense variants affecting these regions makes it seem likely that they disrupt the organization of the base scaffold. (D) Zoom of the coiled-coiled domains of the SMARCC2 proteins. The herein described novel cluster of SMARCC2 missense variants is depicted as red spheres. The affected amino acids (Ala868, Glu893, Met896) are in very close proximity to each other and also to their counterparts in the second SMARCC unit. One of the only five published SMARCE1 (NM 003079.4) missense variants (c.752G>A, p.(Arg251GIn), depicted in magenta) ¹³ is localized in the zinc finger interacting with the SMARCC fingers. This observation again pinpoints that pathogenic amino acid changes in this region could cause alterations in the subunit interactions and dynamics.

Removed to comply	Removed to comply	Removed to comply	Removed to comply
with medRxiv policy.	with medRxiv policy.	with medRxiv policy.	with medRxiv policy.
Removed to comply	Removed to comply	Removed to comply	Removed to comply
with medRxiv policy.	with medRxiv policy.	with medRxiv policy.	with medRxiv policy.
Removed to comply	Removed to comply	Removed to comply	Removed to comply
with medRxiv policy.	with medRxiv policy.	with medRxiv policy.	with medRxiv policy.
Removed to comply	Removed to comply	Removed to comply	
with medRxiv policy.	with medRxiv policy.	with medRxiv policy.	

Figure S3 | White matter involvement and additional neuroimaging findings in individuals with SMARCC2 variants

Multiple non-specific white matter signal alterations are noted both in the parietal and frontal periventricular regions (arrowheads) variably associated with white matter volume loss and enlargement of the lateral ventricles (asterisks) and enlargement of the cerebral CSF spaces (empty arrows). Arachnoid cysts in the left temporal region and posterior cranial fossa are noted respectively in Ind-2 and Ind-11 (thin arrows). Partial ectopic neurohypophysis with T1 hyperintensity extending from the posterior lobe along the pituitary stalk is noted in Ind-25 (dotted arrow). Multiple chronic arterial ischemic infarcts in the left temporal lobe and thalamus (thick arrows) are present in Ind-33 with a normal arterial MR angiography, suggesting possible cerebral embolism.



Figure S4 | Expression assays for SMARCC2 variants c.1834-7C>G and c.3129del

(A) Agarose gel electrophoresis of RT-PCR products of Ind-29 (PT) and control individual (CT) amplified using total RNA extracted from peripheral blood. Detection of residual aberrant product in the individual carrying the c.1834-7C>G variant. M: 100 bps ladder. (B) Sanger sequencing of RT-PCR products. Blue stripe indicates the breakpoint of junction between the exon 19 and the last six bps of intron 19, followed by exon 20. (C) Schematic representation of the alternative splicing of *SMARCC2*. (D) qRT-PCR for *SMARCC2* in Ind-19 (PT) with the variant c.3129del p.(Gly1044Aspfs*17) showing NMD with 68% residual *SMARCC2* RNA expression. One non-carrier sibling was used as control.



Figure S5 | Functional analysis of protein localization

Immunofluorescence staining of transiently overexpressed FLAG-tagged SMARCC2 protein and mutants in HEK293T cells. Yellow: FLAG; blue: DAPI; scale bar: 20 μ m. The observed nuclear expression pattern is unchanged in the mutants.



Figure S6 | Functional analysis of protein interaction

(A) Proximity ligation assay (PLA) of HEK293T cells with transiently overexpressed wildtype and mutant FLAG-tagged SMARCC2. Detection of interaction of FLAG-SMARCC2 with the BAF subunits ARID1B, SMARCA4, SMARCC1, SMARCE1. UT: untransfected; yellow: positive PLA signal indicating interaction; blue: DAPI; scale bar: 10 μ m. (B) Co-Immunoprecipitation (CoIP) of FLAG-SMARCC2. Left panel: representative western blot images of endogenous target proteins (SMARCA4, SMARCC1, SMARCC1, SMARCE1) and the corresponding bait signal (SMARCC2-FLAG). Right panel: box plots of signal quantification normalized to the bait protein (SMARCC2-FLAG) and wildtype sample. Data generated from three independent experiments. P-values were calculated using a one sample t-test (hypothetical mean = 1, significance threshold < 0.05). No significant changes in interactions were detected for all mutants. The interaction of all investigated SMARCC2 mutants with SMARCC1 is increased, but the effect is not statistically significant.

SUPPLEMENTARY TABLES

Table S1 | Overview of all clinical characteristics of SMARCC2 individuals

Group	Phenotype	HPO	Novel cases	Literatu re cases	Truncating variant	Missense/infr ame variant	All cases
	Global developmental delay; Intellectual disability	HP:0001263; HP:0001249	82%, (31/38)	94%, (16/17)	72%, (21/29)	100%, (26/26)	85%, (47/55)
	mild GDD/ID	HP:0011342; HP:0001256	42%, (16/38)	29%, (5/17)	55%, (16/29)	19%, (5/26)	38%, (21/55)
Intellectual and social development	moderate/severe GDD/ID	HP:0011343; HP:0002342; HP:0011344; HP:0010864	39%, (15/38)	65%, (11/17)	17%, (5/29)	81%, (21/26)	47%, (26/55)
	Autistic behavior	HP:0000729	42%, (16/38)	17%, (3/18)	35%, (11/31)	32%, (8/25)	34%, (19/56)
	Behavioral abnormalities	HP:0000708	61%, (23/38)	60%, (9/15)	62%, (18/29)	58%, (14/24)	60%, (32/53)
	Muscular hypotonia	HP:0001252	61%, (23/38)	88%, (15/17)	52%, (15/29)	88%, (23/26)	69%, (38/55)
	Brain imaging abnormality	HP:0410263	60%, (12/20)	62%, (8/13)	50%, (7/14)	68%, (13/19)	61%, (20/33)
	Visual impairment	HP:0000505	32%, (12/38)	36%, (5/14)	21%, (6/29)	48%, (11/23)	33%, (17/52)
Neurological system	Seizures	HP:0001250	27%, (10/37)	29%, (5/17)	25%, (7/28)	31%, (8/26)	28%, (15/54)
	EEG abnormality	HP:0002353	21%, (6/29)	100%, (1/1)	20%, (4/20)	30%, (3/10)	23%, (7/30)
	Muscular hypertonia	HP:0001276	18%, (7/38)	25%, (4/16)	17%, (5/29)	24%, (6/25)	20%, (11/54)
	Hearing impairment	HP:0000365	11%, (4/38)	13%, (2/15)	10%, (3/29)	12%, (3/24)	11%, (6/53)
	Abnormality of the outer ear	HP:0000356	35%, (13/37)	100%, (7/7)	30%, (8/27)	71%, (12/17)	45%, (20/44)
	Thin upper lip vermilion	HP:0000219	41%, (15/37)	50%, (8/16)	48%, (14/29)	38%, (9/24)	43%, (23/53)
	Thick eyebrows	HP:0000574	35%, (13/37)	44%, (7/16)	38%, (11/29)	38%, (9/24)	38%, (20/53)
	Broad philtrum	HP:0000289	22%, (8/37)	70%, (7/10)	28%, (8/29)	39%, (7/18)	32%, (15/47)
	Prominent forehead	HP:0011220	30%, (11/37)	43%, (3/7)	26%, (7/27)	41%, (7/17)	32%, (14/44)
	Thick lower lip vermilion	HP:0000179	22%, (8/37)	50%, (8/16)	24%, (7/29)	38%, (9/24)	30%, (16/53)
	Short philtrum	HP:0000322	27%, (10/37)	36%, (4/11)	28%, (8/29)	32%, (6/19)	29%, (14/48)
Craniofacial anomalies	Long eyelashes	HP:0000527	22%, (8/37)	47%, (7/15)	21%, (6/29)	39%, (9/23)	29%, (15/52)
	Thick alae nasi	HP:0009928	24%, (9/37)	36%, (5/14)	24%, (7/29)	32%, (7/22)	27%, (14/51)
	Wide nose	HP:0000445	22%, (8/37)	36%, (5/14)	24%, (7/29)	27%, (6/22)	25%, (13/51)
	Down-slanting palpebral fissures	HP:0000494	16%, (6/37)	36%, (4/11)	21%, (6/29)	21%, (4/19)	21%, (10/48)
	Upturned nasal tip	HP:0000463	14%, (5/37)	27%, (4/15)	10%, (3/29)	26%, (6/23)	17%, (9/52)
	Wide mouth	HP:0000154	14%, (5/37)	20%, (2/10)	7%, (2/29)	28%, (5/18)	15%, (7/47)
	Hypertelorism	HP:0000316	11%, (4/37)	25%, (3/12)	10%, (3/29)	20%, (4/20)	14%, (7/49)
	Depressed nasal bridge	HP:0005280	11%, (4/37)	14%, (2/14)	10%, (3/29)	14%, (3/22)	12%, (6/51)

Group	Phenotype	HPO	Novel cases	Literatu re cases	Truncating variant	Missense/infr ame variant	All cases
	Macrotia	HP:0000400	5%, (2/37)	11%, (1/9)	7%, (2/28)	6%, (1/18)	7%, (3/46)
	Epicanthic fold	HP:0000286	5%, (2/37)	9%, (1/11)	3%, (1/29)	11%, (2/19)	6%, (3/48)
	Up-slanting palpebral fissures	HP:0000582	5%, (2/37)	0%, (0/11)	0%, (0/29)	11%, (2/19)	4%, (2/48)
	Downturned mouth	HP:0002714	3%, (1/37)	0%, (0/11)	3%, (1/29)	0%, (0/19)	2%, (1/48)
	Abnormal facial shape	HP:0001999	46%, (17/37)	43%,	36%, (10/28)	57%, (13/23)	45%, (23/51)
	Abnormality of skeletal morphology	HP:0011842	31%, (11/35)	38%, (6/16)	26%, (7/27)	42%, (10/24)	33%, (17/51)
	Abnormality of the hand	HP:0001155	33%, (12/36)	25%, (4/16)	29%, (8/28)	33%, (8/24)	31%, (16/52)
	Decreased body weight	HP:0004325	26%, (9/35)	40%, (6/15)	11%, (3/27)	52%, (12/23)	30%, (15/50)
Phenotypical abnormalities of body and face	Abnormality of the foot	HP:0001760	29%, (10/35)	31%, (5/16)	26%, (7/27)	33%, (8/24)	29%, (15/51)
	Abnormality of the eve	HP:0000478	16%, (6/37)	73%, (8/11)	8%, (2/26)	55%, (12/22)	29%, (14/48)
	Short stature	HP:0004322	20%, (7/35)	33%, (5/15)	7%, (2/27)	43%, (10/23)	24%, (12/50)
	Macrocephaly	HP:0000256	15%, (5/34)	21%, (3/14)	16%, (4/25)	17%, (4/23)	17%, (8/48)
	Microcephaly	HP:0000252	12%, (4/34)	7%, (1/14)	4%, (1/25)	17%, (4/23)	10%, (5/48)
	Scoliosis	HP:0002650	26%, (10/38)	31%, (5/16)	17%, (5/29)	40%, (10/25)	28%, (15/54)
	Joint laxity	HP:0001388	16%, (6/37)	7%, (1/14)	21%, (6/28)	4%, (1/23)	14%, (7/51)
	Delayed skeletal maturation	HP:0002750	16%, (3/19)	0%, (0/14)	6%, (1/16)	12%, (2/17)	9%, (3/33)
	Clinodactyly	HP:0030084	8%, (3/37)	7%, (1/15)	7%, (2/29)	9%, (2/23)	8%, (4/52)
	Brachydactyly	HP:0001156	5%, (2/37)	7%, (1/15)	3%, (1/29)	9%, (2/23)	6%, (3/52)
Skeletal anomalies	Prominent interphalangeal joints	HP:0006237	3%, (1/35)	6%, (1/16)	4%, (1/27)	4%, (1/24)	4%, (2/51)
	Pectus excavatum	HP:0000767	3%, (1/38)	7%, (1/14)	0%, (0/29)	9%, (2/23)	4%, (2/52)
	Craniosynostosis	HP:0001363	3%, (1/37)	0%, (0/14)	4%, (1/28)	0%, (0/23)	2%, (1/51)
	Absent distal phalanges of 5th finger	HP:0005807	0%, (0/36)	0%, (0/16)	0%, (0/28)	0%, (0/24)	0%, (0/52)
	Hypertrichosis	HP:0000998	8%, (3/38)	38%, (6/16)	14%, (4/29)	20%, (5/25)	17%, (9/54)
	Sparse/thin scalp hair	HP:0002209	11%, (4/38)	29%, (5/17)	7%, (2/29)	27%, (7/26)	16%, (9/55)
Estadormal anomalias	Delayed eruption of primary teeth	HP:0000680	0%, (0/21)	100%, (2/2)	0%, (0/15)	25%, (2/8)	9%, (2/23)
	Delayed eruption of permanent teeth	HP:0000696	0%, (0/18)	100%, (1/1)	0%, (0/12)	14%, (1/7)	5%, (1/19)
	Aplasia/Hypoplasi a of the nails	HP:0008386	3%, (1/37)	7%, (1/15)	0%, (0/29)	9%, (2/23)	4%, (2/52)
	Microdontia	HP:0000691	0%, (0/34)	NaN%, (0/0)	0%, (0/25)	0%, (0/9)	0%, (0/34)
	Abnormality of the gastrointestinal tract	HP:0011024	17%, (6/36)	100%, (3/3)	12%, (3/24)	40%, (6/15)	23%, (9/39)
Congenital anomalies	Abnormality of the genitourinary system	HP:0000119	17%, (6/35)	100%, (2/2)	13%, (3/23)	36%, (5/14)	22%, (8/37)
	Generalized abnormality of skin	HP:0011354	8%, (3/38)	35%, (6/17)	10%, (3/29)	23%, (6/26)	16%, (9/55)
	Abnormal heart morphology	HP:0001627	8%, (3/36)	23%, (3/13)	11%, (3/28)	14%, (3/21)	12%, (6/49)

Group	Phenotype	HPO	Novel cases	Literatu re cases	Truncating variant	Missense/infr ame variant	All cases
	Hernia	HP:0100790	8%, (3/36)	20%, (3/15)	4%, (1/27)	21%, (5/24)	12%, (6/51)
	Abnormality of the kidney	HP:0000077	9%, (3/34)	NaN%, (0/0)	5%, (1/22)	17%, (2/12)	9%, (3/34)
	Laryngotracheoma lacia	HP:0008755	3%, (1/37)	13%, (2/15)	4%, (1/28)	8%, (2/24)	6%, (3/52)
	Feeding difficulties/failure to thrive	HP:0011968; HP:0001508	47%, (17/36)	59%, (10/17)	33%, (9/27)	69%, (18/26)	51%, (27/53)
	Sleep disturbance	HP:0002360	22%, (8/37)	20%, (3/15)	21%, (6/28)	21%, (5/24)	21%, (11/52)
Miscellaneous	Recurrent infections	HP:0002719	16%, (6/37)	14%, (2/14)	14%, (4/28)	17%, (4/23)	16%, (8/51)
	Recurrent otitis media	HP:0000403	8%, (3/38)	7%, (1/14)	7%, (2/29)	9%, (2/23)	8%, (4/52)
	Oral cleft	HP:0000202	5%, (2/38)	0%, (0/15)	7%, (2/29)	0%, (0/24)	4%, (2/53)

Table S2 | Literature reports of missense variants in other BAF subunits

PMID	DOI	Title
PMID:23637025	10.1002/ajmg.a.35933	Clinical correlations of mutations affecting six components of the SWI/SNF complex: detailed description of 21 patients and a review of the literature
PMID:23661504	10.1002/aur.1301	Quantifying repetitive speech in autism spectrum disorders and language impairment
PMID:23906836	10.1093/hmg/ddt366	A comprehensive molecular study on Coffin-Siris and Nicolaides-Baraitser syndromes identifies a broad molecular and clinical spectrum converging on altered chromatin remodeling
PMID:26364901	10.1002/ajmg.a.37356	Report of a patient with a constitutional missense mutation in SMARCB1, Coffin-Siris phenotype, and schwannomatosis
PMID:27264197	10.1002/ajmg.a.37722	SMARCE1, a rare cause of Coffin-Siris Syndrome: Clinical description of three additional cases
PMID:30209809	10.1111/cge.13436	New SMARCE1 variant in a patient with features overlapping with oculoauriculofrontonasal syndrome
PMID:30879640	10.1016/j.ajhg.2019.02.001	A Syndromic Neurodevelopmental Disorder Caused by Mutations in SMARCD1, a Core SWI/SNF Subunit Needed for Context-Dependent Neuronal Gene Regulation in Flies
PMID:34706719	10.1186/s12920-021-01104- 9	Phenotypic and molecular spectra of patients with switch/sucrose nonfermenting complex-related intellectual disability disorders in Korea
PMID:35579625	10.1016/j.gim.2022.04.010	Discovering a new part of the phenotypic spectrum of Coffin-Siris syndrome in a fetal cohort
PMID:35796094	10.1002/ajmg.a.62889	Evidence for an association between Coffin-Siris syndrome and congenital diaphragmatic hernia

Table S3 | All truncating variants vs. truncating variants without carriers of c.3129delp.(Gly1044Aspfs*17)

Group	Phenotype	НРО	Truncati ng all	Trunca ting no c.3129 del	All cases	p- no3129de IvT (nominal)	p- no3129delv T (FDR- corr.)	OR-no3129delvT (95% Cl)
	Global developmental delay; Intellectual disability	HP:0001263; HP:0001249	72%, (21/29)	87%, (20/23)	85%, (47/55)	0.308112 0	0.308 (1.000)	2.50 (0.51 - 16.69)
Intellectual and	mild GDD/ID	HP:0011342; HP:0001256	55%, (16/29)	65%, (15/23)	38%, (21/55)	0.572948 3	0.573 (1.000)	1.51 (0.43 - 5.52)
social development	moderate/severe GDD/ID	HP:0011343; HP:0002342; HP:0011344; HP:0010864	17%, (5/29)	22%, (5/23)	47%, (26/55)	0.734115 3	0.734 (1.000)	1.33 (0.26 - 6.74)
	Autistic behavior	HP:0000729	35%, (11/31)	17%, (4/23)	34%, (19/56)	0.219951 1	0.220 (1.000)	0.39 (0.08 - 1.61)
	Behavioral abnormalities	HP:0000708	62%, (18/29)	52%, (12/23)	60%, (32/53)	0.575542 7	0.576 (1.000)	0.67 (0.19 - 2.33)
	Muscular hypotonia	HP:0001252	52%, (15/29)	48%, (11/23)	69%, (38/55)	1.000000 0	1.000 (1.000)	0.86 (0.25 - 2.93)
	Brain imaging abnormality	HP:0410263	50%, (7/14)	58%, (7/12)	61%, (20/33)	0.712688 1	0.713 (1.000)	1.38 (0.23 - 8.70)
	Visual impairment	HP:0000505	21%, (6/29)	17%, (4/23)	33%, (17/52)	1.000000 0	1.000 (1.000)	0.81 (0.15 - 4.01)
Neurological system	Seizures	HP:0001250	25%, (7/28)	30%, (7/23)	28%, (15/54)	0.757289 1	0.757 (1.000)	1.31 (0.32 - 5.39)
	EEG abnormality	HP:0002353	20%, (4/20)	27%, (4/15)	23%, (7/30)	0.700273 0	0.700 (1.000)	1.44 (0.22 - 9.59)
	Muscular hypertonia	HP:0001276	17%, (5/29)	17%, (4/23)	20%, (11/54)	1.000000 0	1.000 (1.000)	1.01 (0.17 - 5.44)
	Hearing impairment	HP:0000365	10%, (3/29)	4%, (1/23)	11%, (6/53)	0.620581 8	0.621 (1.000)	0.40 (0.01 - 5.40)
	Abnormality of the outer ear	HP:0000356	30%, (8/27)	33%, (7/21)	45%, (20/44)	1.000000 0	1.000 (1.000)	1.18 (0.29 - 4.79)
	Thin upper lip vermilion	HP:0000219	48%, (14/29)	48%, (11/23)	43%, (23/53)	1.000000 0	1.000 (1.000)	0.98 (0.29 - 3.36)
	Thick eyebrows	HP:0000574	38%, (11/29)	39%, (9/23)	38%, (20/53)	1.000000 0	1.000 (1.000)	1.05 (0.29 - 3.72)
	Broad philtrum	HP:0000289	28%, (8/29)	26%, (6/23)	32%, (15/47)	1.000000 0	1.000 (1.000)	0.93 (0.22 - 3.76)
	Prominent forehead	HP:0011220	26%, (7/27)	19%, (4/21)	32%, (14/44)	0.733416 5	0.733 (1.000)	0.68 (0.12 - 3.23)
	Thick lower lip vermilion	HP:0000179	24%, (7/29)	30%, (7/23)	30%, (16/53)	0.755066 5	0.755 (1.000)	1.37 (0.33 - 5.62)
	Short philtrum	HP:0000322	28%, (8/29)	30%, (7/23)	29%, (14/48)	1.000000 0	1.000 (1.000)	1.15 (0.29 - 4.51)
Craniofacial	Long eyelashes	HP:0000527	21%, (6/29)	26%, (6/23)	29%, (15/52)	0.745523 6	0.746 (1.000)	1.35 (0.30 - 6.04)
anomalies	Thick alae nasi	HP:0009928	24%, (7/29)	30%, (7/23)	27%, (14/51)	0.755066 5	0.755 (1.000)	1.37 (0.33 - 5.62)
	Wide nose	HP:0000445	24%, (7/29)	17%, (4/23)	25%, (13/51)	0.735381 4	0.735 (1.000)	0.67 (0.12 - 3.12)
	Down-slanting palpebral fissures	HP:0000494	21%, (6/29)	22%, (5/23)	21%, (10/48)	1.000000 0	1.000 (1.000)	1.06 (0.22 - 4.97)
	Upturned nasal tip	HP:0000463	10%, (3/29)	13%, (3/23)	17%, (9/52)	1.000000 0	1.000 (1.000)	1.29 (0.16 - 10.72)
	Wide mouth	HP:0000154	7%, (2/29)	4%, (1/23)	15%, (7/47)	1.000000 0	1.000 (1.000)	0.62 (0.01 - 12.64)
	Hypertelorism	HP:0000316	10%, (3/29)	13%, (3/23)	14%, (7/49)	1.000000 0	1.000 (1.000)	1.29 (0.16 - 10.72)
	Depressed nasal bridge	HP:0005280	10%, (3/29)	13%, (3/23)	12%, (6/51)	1.000000 0	1.000 (1.000)	1.29 (0.16 - 10.72)
	Macrotia	HP:0000400	7%, (2/28)	9%, (2/22)	7%, (3/46)	1.000000 0	1.000 (1.000)	1.29 (0.09 - 19.29)

Group	Phenotype	HPO	Truncati ng all	Trunca ting no c.3129 del	All cases	p- no3129de IvT (nominal)	p- no3129delv T (FDR- corr.)	OR-no3129delvT (95% Cl)
	Epicanthic fold	HP:0000286	3%, (1/29)	4%, (1/23)	6%, (3/48)	1.000000 0	1.000 (1.000)	1.27 (0.02 -103.34)
	Up-slanting palpebral fissures	HP:0000582	0%, (0/29)	0%, (0/23)	4%, (2/48)	1.000000 0	1.000 (1.000)	0.00 (0.00 - Inf)
	Downturned mouth	HP:0002714	3%, (1/29)	4%, (1/23)	2%, (1/48)	1.000000 0	1.000 (1.000)	1.27 (0.02 -103.34)
	Abnormal facial shape	HP:0001999	36%, (10/28)	41%, (9/22)	45%, (23/51)	0.774162 6	0.774 (1.000)	1.24 (0.34 - 4.56)
	Abnormality of skeletal morphology	HP:0011842	26%, (7/27)	29%, (6/21)	33%, (17/51)	1.000000 0	1.000 (1.000)	1.14 (0.26 - 4.93)
	Abnormality of the hand	HP:0001155	29%, (8/28)	32%, (7/22)	31%, (16/52)	1.000000 0	1.000 (1.000)	1.16 (0.29 - 4.64)
Phenotypical	Decreased body weight	HP:0004325	11%, (3/27)	14%, (3/21)	30%, (15/50)	1.000000 0	1.000 (1.000)	1.33 (0.16 - 11.10)
abnormalities of body and face	Abnormality of the foot	HP:0001760	26%, (7/27)	29%, (6/21)	29%, (15/51)	1.000000 0	1.000	1.14 (0.26 - 4.93)
,	Abnormality of the eve	HP:0000478	8%, (2/26)	5%, (1/20)	29%, (14/48)	1.000000 0	1.000	0.64 (0.01 - 13.13)
	Short stature	HP:0004322	7%, (2/27)	10%,	24%, (12/50)	1.000000	1.000 (1.000)	1.31 (0.09 - 19.58)
	Macrocephaly	HP:0000256	16%, (4/25)	(2/19)	17%,	0.684277 7	0.684	0.62 (0.05 - 4.98)
	Microcephaly	HP:0000252	4%,	5%, (1/19)	10%,	1.000000	1.000	1.32 (0.02 -108.87)
	Scoliosis	HP:0002650	17%,	17%,	28%,	1.000000	1.000	1.01 (0.17 - 5.44)
	Joint laxity	HP:0001388	21%, (6/28)	23%,	14%,	1.000000	1.000	1.08 (0.22 - 5.07)
	Delayed skeletal maturation	HP:0002750	6%, (1/16)	9%, (1/11)	9%, (3/33)	1.000000	1.000	1.48 (0.02 -125.34)
	Clinodactyly	HP:0030084	7%, (2/29)	9%, (2/23)	8%, (4/52)	1.000000	1.000	1.28 (0.09 - 19.02)
Skeletal	Brachydactyly	HP:0001156	3%, (1/29)	4%, (1/23)	6%, (3/52)	1.000000	1.000	1.27 (0.02 -103.34)
anomalies	Prominent interphalangeal joints	HP:0006237	4%, (1/27)	5%, (1/21)	4%, (2/51)	1.000000 0	1.000 (1.000)	1.29 (0.02 -105.83)
	Pectus excavatum	HP:0000767	0%, (0/29)	0%, (0/23)	4%, (2/52)	1.000000 0	1.000 (1.000)	0.00 (0.00 - Inf)
	Craniosynostosis	HP:0001363	4%, (1/28)	0%, (0/22)	2%, (1/51)	1.000000 0	1.000 (1.000)	0.00 (0.00 - 49.60)
	Absent distal phalanges of 5th finger	HP:0005807	0%, (0/28)	0%, (0/22)	0%, (0/52)	1.000000 0	1.000 (1.000)	0.00 (0.00 - Inf)
	Hypertrichosis	HP:0000998	14%, (4/29)	17%, (4/23)	17%, (9/54)	1.000000 0	1.000 (1.000)	1.31 (0.21 - 8.01)
	Sparse/thin scalp hair	HP:0002209	7%, (2/29)	9%, (2/23)	16%, (9/55)	1.000000 0	1.000 (1.000)	1.28 (0.09 - 19.02)
Ectodormal	Delayed eruption of primary teeth	HP:0000680	0%, (0/15)	0%, (0/9)	9%, (2/23)	1.000000 0	1.000 (1.000)	0.00 (0.00 - Inf)
Ectodermal anomalies	Delayed eruption of permanent teeth	HP:0000696	0%, (0/12)	0%, (0/6)	5%, (1/19)	1.000000 0	1.000 (1.000)	0.00 (0.00 - Inf)
	Aplasia/Hypoplasi a of the nails	HP:0008386	0%, (0/29)	0%, (0/23)	4%, (2/52)	1.000000 0	1.000 (1.000)	0.00 (0.00 - Inf)
	Microdontia	HP:0000691	0%, (0/25)	0%, (0/19)	0%, (0/34)	1.000000 0	1.000 (1.000)	0.00 (0.00 - Inf)
	Abnormality of the gastrointestinal tract	HP:0011024	12%, (3/24)	11%, (2/18)	23%, (9/39)	1.000000 0	1.000 (1.000)	0.88 (0.07 - 8.64)
Congenital anomalies	Abnormality of the genitourinary system	HP:0000119	13%, (3/23)	6%, (1/17)	22%, (8/37)	0.623503 7	0.624 (1.000)	0.43 (0.01 - 5.89)
	Generalized abnormality of skin	HP:0011354	10%, (3/29)	4%, (1/23)	16%, (9/55)	0.620581 8	0.621 (1.000)	0.40 (0.01 - 5.40)

Group	Phenotype	НРО	Truncati ng all	Trunca ting no c.3129 del	All cases	p- no3129de IvT (nominal)	p- no3129delv T (FDR- corr.)	OR-no3129delvT (95% CI)
	Abnormal heart morphology	HP:0001627	11%, (3/28)	9%, (2/22)	12%, (6/49)	1.000000 0	1.000 (1.000)	0.84 (0.06 - 8.06)
	Hernia	HP:0100790	4%, (1/27)	5%, (1/21)	12%, (6/51)	1.000000 0	1.000 (1.000)	1.29 (0.02 -105.83)
	Abnormality of the kidney	HP:0000077	5%, (1/22)	6%, (1/17)	9%, (3/34)	1.000000 0	1.000 (1.000)	1.30 (0.02 -107.77)
	Laryngotracheom alacia	HP:0008755	4%, (1/28)	5%, (1/22)	6%, (3/52)	1.000000 0	1.000 (1.000)	1.28 (0.02 -104.52)
	Feeding difficulties/failure to thrive	HP:0011968; HP:0001508	33%, (9/27)	33%, (7/21)	51%, (27/53)	1.000000 0	1.000 (1.000)	1.00 (0.25 - 3.93)
	Sleep disturbance	HP:0002360	21%, (6/28)	18%, (4/22)	21%, (11/52)	1.000000 0	1.000 (1.000)	0.82 (0.15 - 4.08)
Miscellaneous	Recurrent infections	HP:0002719	14%, (4/28)	14%, (3/22)	16%, (8/51)	1.000000 0	1.000 (1.000)	0.95 (0.12 - 6.37)
	Recurrent otitis media	HP:0000403	7%, (2/29)	9%, (2/23)	8%, (4/52)	1.000000 0	1.000 (1.000)	1.28 (0.09 - 19.02)
	Oral cleft	HP:0000202	7%, (2/29)	9%, (2/23)	4%, (2/53)	1.000000 0	1.000 (1.000)	1.28 (0.09 - 19.02)

Mutation	Orientation	Sequence
c.230C>T	Fw	5'-TAAACTGCTGATCAAATGTTTCCTAGATTTCAAA-3'
(p.Pro77Leu)	Rev	5'-TTGATCAGCAGTTTAGTGAGCGGTGCA-3'
c.640A>G (p.Thr214Ala)	Fw	5'-GTTACGACGCGTGGATCCCAGCGAGTG-3'
	Rev	5'-TCCACGCGTCGTAACTGTCAGGATAGTAGCCC-3'
c.743T>C p.Phe248Ser	Fw	5'-CGACACCTCCAATGAATGGATGAATGAGGAAGAC-3'
	Rev	5'-TCATTGGAGGTGTCGGTGTCCAGGATC-3'
c.1327C>T (p.Arg443Trp)	Fw	5'-CCATTGAGTGGAGGGCTCTCCCCGAGT-3'
	Rev	5'-CCCTCCACTCAATGGCATGAACACTATTGT-3'
c.1919T>C p.(Leu640Pro)	Fw	5'-GCATTTTCCTCGTCTTCCCATTGAAGACCCA-3'
	Rev	5'-AGACGAGGAAAATGCAAGATGCACTCGTCCT-3'
c.2602G>C	Fw	5'-CCCTGGCCCCGCCGCAGTGAAAGCTAAGC-3'
(p.Ala868Pro)	Rev	5'-CGGCGGGGCCAGGGCGGCGGCAGC-3'
c.2678A>G p.(Glu893Gly)	Fw	5'-GCTGGTGGGGACCCAGATGAAAAAGTTGGAGATC-3'
	Rev	5'-TGGGTCCCCACCAGCAGGGCCACCAAAG-3'

Table S4 | Oligonucleotides used for In-Fusion mutagenesis of pCMV-BAF170-FLAG.

Table S5 | Antibodies and dilutions used.

Antibody	Supplier & cat. no.	Method	Dilution
mouse monoclonal ARID1B	Abcam	PLA	1:70
	2007401	Western	1:250
mouse monoclonal BRG1 (SMARCA4)	Santa Cruz	PLA	1:250
		Western	1:1 000
mouse monoclonal FLAG	Sigma	PLA/IF	1:500
	1 1004	Western	1:10 000
rabbit polyclonal FLAG	Sigma	PLA/IF	1:500
	F7423	Western	1:1 000
rat monoclonal FLAG	Novus biologicals NBP1-06712SS	PLA/IF	1:100
rabbit polyclonal SMARCC1	Cell Signaling	PLA	1:250
	#11956	Western	1:1 000
rabbit polyclonal SMARCD1	Santa Cruz	PLA	1:500
	sc-135843	Western	1:1000
rabbit polyclonal SMARCE1	betyhl laboratories	PLA	1:50
	Α 300-810Α-1	Western	1:1 000
Cy3 conjugated goat anti rat	dianova	PLA/IF	1:300

	112-165-003		
Cy3 conjugated goat anti mouse	dianova 115-165-146	IF	1:300
HRP conjugated anti mouse	Invitrogen G-21040	Western	1:10 000
HRP conjugated anti rabbit	Cell Signaling #7074	Western	1:3 000
Tidy Blot reagent	BioRad STAR209P	Western	1:200

SUPPLEMENTARY REFERENCES

- Chen CA, Lattier J, Zhu W, et al. Retrospective analysis of a clinical exome sequencing cohort reveals the mutational spectrum and identifies candidate disease-associated loci for BAFopathies. *Genet Med Off J Am Coll Med Genet*. 2022;24(2):364-373. doi:10.1016/j.gim.2021.09.017
- Li D, Downes H, Hou C, et al. Further supporting SMARCC2-related neurodevelopmental disorder through exome analysis and reanalysis in two patients. *Am J Med Genet A*. 2022;188(3):878-882. doi:10.1002/ajmg.a.62597
- Sobreira N, Schiettecatte F, Valle D, Hamosh A. GeneMatcher: a matching tool for connecting investigators with an interest in the same gene. *Hum Mutat*. 2015;36(10):928-930. doi:10.1002/humu.22844
- Machol K, Rousseau J, Ehresmann S, et al. Expanding the spectrum of BAF-related disorders: de novo variants in SMARCC2 cause a syndrome with intellectual disability and developmental delay. *Am J Hum Genet*. 2019;104(1):164-178. doi:10.1016/j.ajhg.2018.11.007
- Yi S, Li M, Yang Q, et al. De novo SMARCC2 variant in a chinese woman with Coffin-Siris syndrome 8: a case report with mild intellectual disability and endocrinopathy. *J Mol Neurosci MN*. 2022;72(6):1293-1299. doi:10.1007/s12031-022-02010-0
- Lo T, Kushima I, Aleksic B, et al. Sequencing of selected chromatin remodelling genes reveals increased burden of rare missense variants in ASD patients from the Japanese population. *Int Rev Psychiatry Abingdon Engl.* 2022;34(2):154-167. doi:10.1080/09540261.2022.2072193
- Gofin Y, Zhao X, Gerard A, et al. Evidence for an association between Coffin-Siris syndrome and congenital diaphragmatic hernia. *Am J Med Genet A*. 2022;188(9):2718-2723. doi:10.1002/ajmg.a.62889
- Sun H, Zhang S, Wang J, et al. Expanding the phenotype associated with SMARCC2 variants: a fetus with tetralogy of Fallot. *BMC Med Genomics*. 2022;15(1):40. doi:10.1186/s12920-022-01185-0
- Xi Q, He W, Zhang XHF, Le HV, Massagué J. Genome-wide impact of the BRG1 SWI/SNF chromatin remodeler on the transforming growth factor β transcriptional program. *J Biol Chem*. 2008;283(2):1146-1155. doi:10.1074/jbc.M707479200
- 10. Wittmann MT, Katada S, Sock E, et al. scRNA sequencing uncovers a TCF4dependent transcription factor network regulating commissure development in mouse. *Development*. 2021;148(14):dev196022. doi:10.1242/dev.196022
- 11. He S, Wu Z, Tian Y, et al. Structure of nucleosome-bound human BAF complex. *Science*. 2020;367(6480):875-881. doi:10.1126/science.aaz9761
- 12. Nixon KCJ, Rousseau J, Stone MH, et al. A syndromic neurodevelopmental disorder caused by mutations in SMARCD1, a core SWI/SNF subunit needed for context-dependent neuronal gene regulation in flies. *Am J Hum Genet.* 2019;104(4):596-610. doi:10.1016/j.ajhg.2019.02.001
- 13. Yano S, Fujimoto A, Morin-Leisk J, et al. New *SMARCE1* variant in a patient with features overlapping with oculoauriculofrontonasal syndrome. *Clin Genet*. 2018;94(5):487-488. doi:10.1111/cge.13436